54. Bevis K.S., Biggio J.R. Cervical conization and the risk of preterm delivery. Am J Obstet Gynecol 2011; 205:19–27.

55. Jin G., LanLan Z., Li C., Dan Z. Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic reviewand meta-analysis. Arch Gynecol Obstet. 2014 Jan; 289(1):85–99.

56. Ozog D.M., Rkein A.M., Fabi S.G., Gold M.H., Goldman M.P., Lowe N.J., Martin G.M., Munavalli G.S. Photodynamic Therapy: A Clinical Consensus Guide. Dermatol Surg. 2016 Jul; 42(7):804–27.

57. Chilakamarthi U., Giribabu L. Photodynamic Therapy: Past, Present and Future. Chem Rec. 2017 Aug; 17(8):775–802.

58. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., Hahn S.M., Hamblin M.R., Juzeniene A., Kessel D., Korbelik M., Moan J., Mroz P., Nowis D., Piette J., Wilson B.C., Golab J. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011 Jul-Aug; 61(4):250–81.

59. Tosti G., Iacobone A.D., Preti E.P., Vaccari S., Barisani A., Pennacchioli E., Cantisani C. The Role of Photodynamic Therapy in the Treatment of Vulvar Intraepithelial Neoplasia Biomedicines. 2018 Feb 2; 6(1). pii: E13

60. Fu Y., Bao Y., Hui Y., Gao X., Yang M., Chang J. Topical photodynamic therapy with 5-aminolevulinic acid for cervical high-risk HPV infection Photodiagnosis Photodyn Ther. 2016 Mar; 13:29–33.

61. Choi M.C., Lee C., Kim S.J. Efficacy and safety of photodynamic therapy for cervical intraepithelial neoplasia: a systemic review Photodiagnosis Photodyn Ther. 2014 Dec; 11(4):479–80.

62. Frega A., Sesti F., De Sanctis L., Pacchiarotti A., Votano S., Biamonti A., Sopracordevole F., Scirpa P., Catalano A., Caserta D., Gentile M., Schimberni M., Moscarini M. Pregnancy outcome after loop electrosurgical excision procedure for cervical intraepithelial neoplasia. Int J Gynaecol Obstet. 2013 Aug; 122(2):145–9.

63. Maździarz A. Successful Pregnancy and Delivery Following Selective Use of Photodynamic Therapy in Treatment of the Cervix and Vulva Diseases. Photodiagnosis Photodyn Ther. 2019 Jul 9. pii: S1572–1000(18)30348-X.

64. Hancock G., Hellner K., Dorrell L. Therapeutic HPV vaccines. Best Pract Res Clin Obstet Gynaecol. 2018 Feb; 47:59–72

65. Ley C., Bauer H.M., Reingold A., et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst 1991; 83:997–1003.

66. Winer R.L., Hughes J.P., Feng Q., et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354(25):2645–54.

67. Castle P.E., Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect. 2016 Feb; 144(3):449–68.

68. CDC. Human papillomavirus vaccination coverage among adolescent girls, 2007–2012, and postlicensure vaccine safety monitoring, 2006–2. Morbidity and Mortality Weekly Report 2013; 62: 591–595.

69. Gee J., et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011; 29: 8279–8284.

70. Anon. Global Advisory Committee on Vaccine Safety. Statement on the continued safety of HPV vaccination. 2014 (http://www.who.int/vaccine_safety/committee/ topics/hpv/GACVS_Statement_HPV_12_Mar_2014. pdf). Accessed 9 November 2014.

71. Malagon T., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infectious Diseases 2012; 12: 781–789.

72. Brown D.R., Kjaer S.K., Sigurdsson K., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009; 199:926.

73. Crowe E., et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. British Medical Journal 2014; 348: g1458.

74. Donovan B., et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infectious Diseases 2011; 11: 39–44.

75. Markowitz L.E., et al. Reduction in human papilloma-virus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. Journal of Infectious Diseases 2013; 208: 385–393.

76. Anon. FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV. 2015 (http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm426485.htm). Accessed 3 April 2015.

77. Hildesheim A., et al. Effect of human papillomavirus 16/ 18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. Journal of the American Medical Association 2007; 298: 743–753.

78. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915.

79. Stier E.A., Chiao E.Y. Anal Cancer and Anal Cancer precursors in Women with a History of HPV-Related Dysplasia and Cancer. Semin Colon Rectal Surg. 2017; 28(2):97–101. doi:10.1053/j.scrs.2017.04.008.

80. Anal Cancer Incidence in the United States, 1977–2011: Distinct Patterns by Histology and Behavior.

81. Shiels M.S., Kreimer A.R., Coghill A.E., Darragh T.M., Devesa S.S. Cancer Epidemiol Biomarkers Prev. 2015 Oct; 24(10):1548–56.

82. Zhai L., Tumban E. Gardasil-9: A global survey of projected efficacy. Antiviral Res. 2016 Jun; 130:101–9.

Во внутреннем оформлении использованы иллюстрации: one line man, widmachka, samui, ararat.art, Channarong Pherngjanda, geraria, Rvector, CloudyStock, LuckyStep, DODOMO, Morphart Creation, Ermak Oksana, tanshy, Zonda, Rvector, PYRAMIS, arip teguh santoso, chubphong, iconvectorstock, Sergey Korkin, Simple Line, Valenty, pantid123, Benn Beckman, Burunduk's / Shutterstock.com Используется по лицензии от Shutterstock.com